Sequana Medical NV (SEQUA.BR)
5.52 €
-0.04 (-0.72%)
Rating:
Recommendation:
-
| Symbol | SEQUA.BR |
|---|---|
| Price | 5.52 € |
| Beta | 0.861 |
| Volume Avg. | 0.00M |
| Market Cap | 131.556M |
| Shares () | - |
| 52 Week Range | 4.86-7.5 |
| 1y Target Est | - |
| DCF Unlevered | SEQUA.BR DCF -> | |
|---|---|---|
| DCF Levered | SEQUA.BR LDCF -> | |
| ROE | -228.78% | Strong Sell |
| ROA | -43.29% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 136.35% | Buy |
| P/E | - | |
| P/B | 5.80 | Strong Buy |
About
Download (Excel)Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.